Symptomatic and Functional Improvement in Employed Depressed Patients: A Double-Blind Clinical Trial of Desvenlafaxine Versus Placebo
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This is the first study to assess the efficacy of desvenlafaxine (administered as desvenlafaxine succinate) for improving depressive symptoms and functioning exclusively in employed patients with major depressive disorder (MDD). METHODS: Gainfully employed (≥20 h/wk) male and female outpatients with MDD were randomly assigned (2:1 ratio) to 12 weeks of double-blind treatment with desvenlafaxine 50 mg/d or placebo. Analysis of covariance was used to compare differences in week 12 adjusted mean changes from baseline on the 17-item Hamilton Depression Rating Scale (HAM-D₁₇) (primary outcome) and Sheehan Disability Scale (SDS) (key secondary outcome) in the intent-to-treat (ITT) population. A predefined, modified ITT population (ie, those in the ITT population with baseline HAM-D₁₇ ≥20) was also analyzed. Tolerability was assessed by recording adverse events and change on the Arizona Sexual Experience Scale. RESULTS: Baseline HAM-D₁₇ scores for desvenlafaxine (n = 285) and placebo (n = 142) were 22.0 and 21.8, whereas baseline SDS scores were 19.8 and 20.4. Adjusted mean differences between desvenlafaxine and placebo were 2.1 (95% confidence interval [CI], 0.78-3.46; P = 0.002) on the HAM-D₁₇ and 1.3 (95% CI, -0.09 to 2.76; P = 0.067) on the SDS. For the modified ITT sample, desvenlafaxine (n = 208) and placebo (n = 102), baseline HAM-D₁₇ scores were 23.8 and 23.9; the SDS baseline scores were 20.1 and 20.8. Mean differences were 2.6 (95% CI, 0.93-4.22; P = 0.002) on the HAM-D₁₇ and 2.1 (95% CI, 0.36-3.76; P = 0.017) on the SDS. Adverse events and Arizona Sexual Experience Scale scores were comparable between groups. CONCLUSIONS: Desvenlafaxine 50 mg/d was efficacious for treating MDD in gainfully employed adults. Between-group differences on the SDS narrowly missed statistical significance in the ITT population alone, but the totality of data suggests functional improvements with active treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“In addition, employment status may be an important source of variance in clinical trial outcomes: unemployed patients are significantly less likely to experience a remission of symptoms compared with those who are employed.(17) Considering these factors, it is surprising that no published large-scale clinical trials h…”
BackgroundAntidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959 · cited 1×
“As a result, current definitions of response and remission are defined solely using symptomatic measures.(12) However, symptombased rating scales do not fully assess the patient’s level of functioning, which may continue to be impaired even when the patient is experiencing only mild depressive symptoms.”
BackgroundCost of Lost Productive Work Time Among US Workers With Depression
Stewart, W. F. (2003) · JAMA · doi:10.1001/jama.289.23.3135 · Cited by 1,421 · cited 1×
“Using data from the Depressive Disorders Study, researchers have estimated the cost to employers of depressionrelated presenteeism and absenteeism to be $44 billion per year.(9) As a result, the poor work performance observed in employees with depression is a threat to their continued employment and financial security.”
MethodThe Economic Burden of Depression in the United States: How Did It Change Between 1990 and 2000?
Greenberg, P. E., Kessler, R. C., Birnbaum, H. G., Leong, S. A., Lowe, S. W., Berglund, P. A., & Corey-Lisle, P. K. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1211 · Cited by 1,280
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109 · cited 1×
“First, it has been shown that the placebo effect across studies has been increasing over time.(34) Second, the 2:1 randomization ratio of drug versus placebo will likely have enhanced patient’s expectations of receiving the active treatment.”
BackgroundCognitive Therapy vs Medications in the Treatment of Moderate to Severe Depression
DeRubeis, R. J., Hollon, S. D., Amsterdam, J. D., Shelton, R. C., Young, P. R., Salomon, R. M., O’Reardon, J. P., Lovett, M. L., Gladis, M. M., Brown, L. L., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.4.409 · Cited by 989
Kessler, R. C., Akiskal, H. S., Ames, M., Birnbaum, H., Greenberg, P., .A, R. M., Jin, R., Merikangas, K. R., Simon, G. E., & Wang, P. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.9.1561 · Cited by 868
Kessler, R. C., Akiskal, H. S., Ames, M., Birnbaum, H., Greenberg, P., .A, R. M., Jin, R., Merikangas, K. R., Simon, G. E., & Wang, P. S. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1561 · Cited by 868
Health and disability costs of depressive illness in a major U.S. corporation
Druss, B. G., Rosenheck, R. A., & Sledge, W. H. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.8.1274 · Cited by 395 · cited 1×
“T he functional impairment and disability costs associated with major depressive disorder (MDD) have been estimated to be greater than what is observed with other chronic medical illnesses, such as diabetes, hypertension, and heart disease.(1) Approximately 7% of full-time working adults experience an episode of MDD e…”
Background
Cited by
Toward a Neuroimaging Treatment Selection Biomarker for Major Depressive Disorder
McGrath, C. L., Kelley, M. E., Holtzheimer, P. E., Dunlop, B. W., Craighead, W. E., Franco, A. R., Craddock, R. C., & Mayberg, H. S. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.143 · Cited by 561
Self-citationInterventions to improve return to work in depressed people
Nieuwenhuijsen, K., Faber, B., Verbeek, J. H., Neumeyer-Gromen, A., Hees, H. L., Verhoeven, A. C., van der Feltz-Cornelis, C. M., & Bültmann, U. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006237.pub3 · Cited by 299
Spielmans, G. I., Berman, M. I., Linardatos, E., Rosenlicht, N. Z., Perry, A., & Tsai, A. C. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001403 · Cited by 275
Restoring function in major depressive disorder: A systematic review
Sheehan, D. V., Nakagome, K., Asami, Y., Pappadopulos, E. A., & Boucher, M. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.02.029 · Cited by 182
Lam, R. W., Parikh, S. V., Ramasubbu, R., Michalak, E. E., Tam, E. M., Axler, A., Yatham, L. N., Kennedy, S. H., & Manjunath, C. V. (2013) · British Journal of Psychiatry · doi:10.1192/bjp.bp.112.125237 · Cited by 56
Metadata
- Authors
- Dunlop, B. W., Reddy, S., Yang, L., Lubaczewski, S., Focht, K., & Guico-Pabia, C. J.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2011-10
- Volume
- 31
- Issue
- 5
- Pages
- 569-576
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2056032313
- Cited by
- 75
- References
- 11
- FWCI
- 4.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Symptomatic and Functional Improvement in Employed Depressed Patients: A Double-Blind Clinical Trial of Desvenlafaxine Versus Placebo. https://app.cochat.ai/papers/10.1097/jcp.0b013e31822c0a68
- The paper
- Dunlop, B. W., Reddy, S., Yang, L., Lubaczewski, S., Focht, K., & Guico-Pabia, C. J. (2011). Symptomatic and Functional Improvement in Employed Depressed Patients: A Double-Blind Clinical Trial of Desvenlafaxine Versus Placebo. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e31822c0a68
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.